Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Mehr anzeigen
Palatin Provides Update on Anticipated 2025 Corporate Milestones PR Newswire CRANBURY, N.J., Jan. 28, 2025 Obesity programs:Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus...
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy PR Newswire CRANBURY, N.J., Dec. 19, 2024 Open label study designed to evaluate the...
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds PR Newswire CRANBURY, N.J., Dec. 16, 2024 CRANBURY, N.J., Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies...
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis PR Newswire CRANBURY, N.J., Nov. 25, 2024 Oral PL8177...
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results PR Newswire CRANBURY, N.J., Nov. 14, 2024 Obesity programs:Core focus on obesity includes exploratory co-administration...
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 PR Newswire CRANBURY, N.J., Nov. 8, 2024 CRANBURY, N.J., Nov. 8, 2024...
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 PR Newswire CRANBURY, N.J., Nov. 4, 2024 Oral PL7737 significantly...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.032 | -3.51648351648 | 0.91 | 0.9499 | 0.79 | 693478 | 0.82535551 | CS |
| 4 | -0.372 | -29.76 | 1.25 | 1.3227 | 0.79 | 415204 | 0.93012148 | CS |
| 12 | -0.332 | -27.4380165289 | 1.21 | 1.45 | 0.7164 | 462118 | 0.98660034 | CS |
| 26 | -0.622 | -41.4666666667 | 1.5 | 1.72 | 0.68 | 351471 | 1.05281621 | CS |
| 52 | -2.922 | -76.8947368421 | 3.8 | 4.65 | 0.68 | 365519 | 1.71313055 | CS |
| 156 | 0.4639 | 112.026080657 | 0.4141 | 8.6 | 0.1811 | 353147 | 1.31949603 | CS |
| 260 | 0.233 | 36.1240310078 | 0.645 | 8.6 | 0.1811 | 1549381 | 0.75765115 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
